Sejahteraraya Anugrahjaya Tbk

SRAJ

Overview

SRAJ Overview

PT Sejahteraraya Anugrahjaya Tbk is an Indonesia-based company engaged in hospital and health care services. The Company’s segments include In-patient, including supporting services, and Out-patient, including supporting services. The Company operates over six hospitals, including Mayapada Hospital Tangerang (MHTG), Mayapada Hospital Jakarta Selatan (MHJS), Mayapada Hospital Kuningan (MHKN), Mayapada Hospital Bogor BMC (MHBG), Mayapada Hospital Surabaya (MHSB) and Mayapada Hospital Bandung (MHBD). It has a range of centers, which include neuroscience center, uro-nephrology center, cardiovascular center, gastrohepatology, oncology center, orthopedic center, obstetrics and gynecology center, pulmonology and internal medicine, pediatric center, dermato and aesthetic clinic, gastrointestinal and liver center, spine and arthroplasty center, sports injury treatment and performance center, and post-Covid recovery and rehabilitation center.

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: SRAJ

Main
Market Cap.
IDR 20.58Trillion

~$1.30B USD

Industry
Healthcare Providers
Sub-Industry
Healthcare Providers
Sector
Healthcare

Valuation

SRAJ Valuation Metrics

1,715

IDR
0.0%

Closing Price on 2024-04-05

Price to Equity

-433.09

P/E

At -433.09x P/E TTM, SRAJ.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Price to Book

11.10

P/B

At 11.10x P/B TTM, SRAJ.JK is trading at a premium to its peers in the Healthcare Equipment & Providers sector (avg 1.8x).

Price to Sales

8.76

P/S

At 8.76x P/S TTM, SRAJ.JK is trading at a premium to its peers in the Healthcare Equipment & Providers sector (avg 3.0x).

Valuing Sejahteraraya Anugrahjaya Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Healthcare Equipment & Providers sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Sejahteraraya Anugrahjaya Tbk relative to other stocks in the Healthcare Equipment & Providers sector

Price/Cash Flow
248.30x
Price/Forward Earnings
-
Enterprise Value/Revenue
9.23x
Enterprise Value/EBITDA
107.76x
PEG Ratio
-3.65x

Analyst Ratings

No analyst ratings available yet.

Valuation Recap of SRAJ stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of -433.09x is below the ID market average of 8.09x and is trading at a discount to peers in the Healthcare Equipment & Providers sector (23.78x). In fact, less than 25% of its peers trade at a lower P/E ratio than SRAJ.●●●
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 11.10x is above the peers average of 1.80x in the Healthcare Equipment & Providers sector. SRAJ trades at a higher P/B ratio than >75% of its peers in the Healthcare Equipment & Providers sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 8.76x is above the peers average of 3.00x in the Healthcare Equipment & Providers sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of SRAJ's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. SRAJ's P/CF ratio of 248.30x is considered a relatively high ratio by analysts.
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. SRAJ's EV/R ratio of 9.23x is considered a relatively high ratio The average EV/R ratio for the Healthcare Equipment & Providers sector is 2.98x.
Max 3

Peers

SRAJ Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.17.82T8.52T 5.54T 0.48T 36.964.82
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk8.79T11.31T 12.93T 1.41T 6.221.14
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
OMEDPT Jayamas Medica Industri Tbk5.33T2.46T 1.63T 0.22T 23.782.50
Competitiveness Recap of SRAJ stock
WeightNotesScore
High
At a market cap of IDR 20,581.20 billion, SRAJ.JK ranks 4 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of -433.09, SRAJ.JK ranks 10 out of 10 companies in the Healthcare sector for P/E value. The average PE is -17.95 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of -433.09, SRAJ.JK is trading at a lower PE than that of its subsector peers in Healthcare Equipment & Providers (median of 23.78). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.
Max 2
Medium
At a revenue of IDR 2.35 trillion, SRAJ.JK ranks 8 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of -IDR 0.05 trillion, SRAJ.JK ranks 10 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of SRAJ

Growth Forecasts

No data available

Sector Benchmark

Healthcare Equipment & Providers companies in Indonesia are growing at a projected rate of 23.68% against the IDX average of +12.0%.

Healthcare Equipment & Providers sector overview
No data is available for SRAJ at the moment.
Future growth prospect of SRAJ
WeightNotesScore
High
SRAJ's projected growth rate of 23.68% is above the ID market average of 11.98%.●●●
Max 3
High
The Healthcare Equipment & Providers sub-sector is projected to grow revenue by 22.86% in 2024. This number is higher than the previous year 2023's growth rate of 9.87%. This bodes well for SRAJ's revenue growth prospects in the next 2 years. ●●●
Max 3
Medium
The Healthcare Equipment & Providers sub-sector is projected to increase earnings by 29.30% in 2024. This number is higher than the previous year 2023's EPS growth of 9.53%. This bodes well for SRAJ's earnings growth prospects in the next 2 years. ●●●
Max 3
Medium
SRAJ and its peers in the Healthcare Equipment & Providers sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 15.99% in 2024 while revenue growth is projected to increase by 17.01%. These macroeconomic trends will likely be a tailwind for SRAJ's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Grace Dewi Riady15.2 years
Jane Dewi Tahir
Director
Jon Lie Sarpin
Director
NamePositionShares%
Dato'Sri Prof. Dr Tahir MbaCommissioner2,500,0000.02
Jane Dewi TahirDirector50,000,0000.42
Jonathan TahirPresident Commissioner58,252,8000.49
Expressed in millions IDR, unless otherwise stated

Ownership

SRAJ Ownership

Others
5.46%
Insiders
94.54%
Institutions
0%
NameNumber of SharesOwnership (%)Value
Pt Surya Cipta Inti Cemerlang7,199,214,74359.9912,346.65B
High Pro Investments Limited2,179,993,00218.173,738.69B
Wing Harvest Limited1,855,665,75415.463,182.47B
Public (Scripless)655,079,1465.451,123.46B
Jonathan Tahir58,252,8000.4999.90B
Jane Dewi Tahir50,000,0000.4285.75B
Dato'Sri Prof. Dr Tahir Mba2,500,0000.024.29B

Largest Institutional Buy

PMB Investment Berhad
Bought 31-01-2024
+640,000 shares

Largest Institutional Sell

No data is available for SRAJ at the moment.

Institutional Transactions

Tracking institutional transactions buying / selling of SRAJ stock